Royalty Pharma PLC Class A RPRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RPRX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- GBP 498.00
- Day Range
- GBP 482.00–482.00
- 52-Week Range
- GBP 463.34–531.50
- Bid/Ask
- GBP 482.00 / GBP 482.00
- Market Cap
- GBP 215.31 Bil
- Volume/Avg
- 20,600 / 6,339
Key Statistics
- Price/Earnings (Normalized)
- 16.37
- Price/Sales
- 6.95
- Dividend Yield (Trailing)
- 2.86%
- Dividend Yield (Forward)
- 2.91%
- Total Yield
- 5.38%
Company Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Value
- Total Number of Employees
- 89
- Website
- https://www.royaltypharma.com
Competitors
Valuation
|
Metric
|
RPRX
|
VRTX
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 16.37 | 26.13 | 13.81 |
Price/Book Value | 1.94 | 5.83 | 1.61 |
Price/Sales | 6.95 | 10.50 | 2.45 |
Price/Cash Flow | 5.49 | 27.24 | 13.18 |
Price/Earnings
RPRX
VRTX
PFE
Financial Strength
|
Metric
|
RPRX
|
VRTX
|
PFE
|
|---|---|---|---|
Quick Ratio | 7.87 | 3.60 | 0.58 |
Current Ratio | 7.90 | 3.99 | 0.91 |
Interest Coverage | 9.70 | 86.38 | 0.74 |
Quick Ratio
RPRX
VRTX
PFE
Profitability
|
Metric
|
RPRX
|
VRTX
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | −4.87% | 19.46% | 4.98% |
Return on Equity (Normalized) | −13.28% | 25.47% | 10.90% |
Return on Invested Capital (Normalized) | −4.22% | 21.34% | 7.28% |
Return on Assets
RPRX
VRTX
PFE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hrxsbbzv | Dbmy | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vrtvlpftb | Hjsbdq | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Szywqqxjv | Khgfpt | $97.8 Bil | |
MRNA
| Moderna Inc | Jjydszjn | Fpcn | $41.3 Bil | |
ARGX
| argenx SE ADR | Mgbdxnfx | Pslp | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Fhfftvd | Syg | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dwrslysyd | Ldxxd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Swnqlyxr | Gqlrlm | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hnrggbswf | Nggzpv | $12.5 Bil | |
INCY
| Incyte Corp | Qvdfjdk | Nkvkj | $11.6 Bil |